

# FORMS RELATING TO LISTING

## FORM F

### The Growth Enterprise Market (GEM)

#### Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

**Company name :** Essex Bio-Technology Limited

**Stock code (ordinary shares):** 8151

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 3<sup>rd</sup> July, 2002.

#### A. *General*

Place of incorporation	:	The Cayman Islands
Date of initial listing on GEM	:	27 <sup>th</sup> June, 2001
Name of Sponsor(s)	:	Dao Heng Securities Limited (Joint Sponsor) Deloitte & Touche Corporate Finance Ltd (Joint Sponsor)
Names of directors : ( <i>please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive</i> )	:	<u>Executive Directors:</u> Ngiam Mia Je Patrick Fang Haizhou Zhong Sheng  <u>Non-executive Directors:</u> Wong Kui Ming Albert Wai-Kit Chan  <u>Independent non-executive Directors:</u> Fung Chi Ying Mauffrey Benoit Jean Marie
Name(s) of substantial shareholder(s) (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	:	Essex Holdings Limited Ngiam Mia Je Patrick Ngiam Mia Kiat Benjamin Lauw Hui Kian

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company	: N/A
Financial year end date	: 31 <sup>st</sup> December
Registered address	: Century Yard, Cricket Square, Hutchins Drive, P.O. Box 2681 GT, George Town, Grand Cayman, British West Indies
Head office and principal place of business	: Room 2818, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong
Web-site address (if applicable)	: www.essexbio.com
Share registrar	: Secretaries Limited 5 <sup>th</sup> Floor, Wing On Centre, 111 Connaught Road Central, Hong Kong
Auditors	: Horwath Hong Kong CPA Limited

**B. Business activities**

The Group specialises in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and organ wounds and the research and development of biopharmaceutical products for the treatment and healing of surface wounds and organ wounds and the research and development of biopharmaceutical products for the treatment of stomach ulcers and nervous system damages and diseases. The Group currently has two commercialised biopharmaceutical products, namely Beifuji in liquid form and lyophilised powder form and Beifushu in eye-drop form for the treatment and healing of acute and chronic surface wounds and corneal wounds respectively.

**C. Ordinary shares**

Number of ordinary shares in issue	: 546,820,000
Par value of ordinary shares in issue	: HK\$0.10 each
Board lot size (in number of shares)	: 4,000 Shares
Name of other stock exchange(s) on which ordinary shares are also listed	: N/A

**D. Warrants**

Stock code	: N/A
Board lot size	: N/A
Expiry date	: N/A
Exercise price	: N/A

Conversion ratio : N/A  
(Not applicable if the warrant is  
denominated in dollar value of  
conversion right)

No. of warrants : N/A  
outstanding

No. of shares falling : N/A  
to be issued upon the  
exercise of outstanding warrants

**E. Other securities** : N/A

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

### **Responsibility statement**

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

---

Ngiam Mia Je Patrick

---

Wong Kui Ming

---

Fang Haizhou

---

Fung Chi Ying

---

Zhong Sheng

---

Mauffrey Benoit Jean Marie

---

Albert Wai-Kit Chan